Académique Documents
Professionnel Documents
Culture Documents
GROUP 9: EQUILIBRIUM
MEMBERS: POOJA VERMA(1421337),
VINEET RAINA(1421332)
SAYON DAS(1421328),
DISHANT BANSAL(1421309),
BHAVANA KONETI(1421341),
KARTHIK ESHWARAN(1421315)
INTRODUCTION TO
PHARMACEUTICAL INDUSTRY IN
INDIA
1930: First pharmaceutical company called Bengal Chemicals and pharmaceutical works ws started
which exists even today as government owned drug manufacturers.
1970: Patent act was introduced which saw a major breakthrough in pharma industry and gave
boost to the industry.
1980: The industry values $25 million compared to $25 billion in 2014.
1992: With liberalization Indian pharma industry detached from the then included in manufacturing
industry and started expanding in India and abroad attracting foreign investments.
According to Indian Brand equity foundation the Indian pharma industry is growing at a CAGR of
17.4 % between 2012-2016 (forecasted).
In terms of volume India is 1.4% in value standing at 14th position and 10% in terms of volume
standing at 3rd position.
Today Indian companies are investing heavily on R&D , reengineering, increase exports in more
than 200 countries, penetrating in the Indian market and expanding abroad. This has led
Pharmaceutical industry to be key drivers of economy.
Pharma
Active
pharmaceutic
al
ingredients/B
ulk drugs
Branded
Formulatio
ns
Generic
Chronic
Acute
Cardiovascular
,neurological,a
ntidiabetes,gastr
o intestinal
antiinfectives,Resp
iraoty,pain,gyn
ecology
27%
Indian Companies
MNCs
73%
Key International
players are AbottLaboratories, GlaxoSmithKline, Pfizer
Key Domestic Players
Sun Pharma, Lupin Ltd, Cipla, Dr Reddys,
36
30
30
25
25
20
21
15
10
14
10
11
2008
2009
16
17
2011
2012
5
0
2010
2013
2014
2015
2016
Source: all Indian origin chemists & distributors, dep. of pharmaceuticals, planning commission
report www.ibef.org
Current growth outlook CAGR is at 17.4% from 2008 to 2016. Current value of Indian pharmaceutical
industry is 25 billion which is expected to grow to 36 billion.
This is resulted due to various reasons such as:
RISE IN PER CAPITA INCOME: $ 1570
RISE INVESTMENT IN HEALTHCARE INDUSTRY
TOTAL GOVERNMENT EXPENDITURE in pharma: $ 27 billion
RISE IN G.D.P OF INDIA: (average growth of 5% from 2009-2013) $1.87 trillion (nominal: 10th; 2013)
HIGHER FOREIGN INVESTMENT (FDI @ 100%): $ 10.3 billion
INCREASED LITERACY & AWARENESS ABOUT HEALTHCARE: literacy at 74%.
HUMAN DEVELOPMENT INDEX: 0.586 (135th in the world)
The Enactment of WTOs Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement
which mandated patent protection on both products and process.
The Expansion of bio-technology and research & development in India.
HHI
Market Share Of Companies in % (on basis of Net Revenue)
Companies
Sun Pharma
8.4
Dr Reddy
7.8
Lupin
6.4
Cipla
5.2
Aurobindo Pharma
3.6
Cadila Health
2.4
Ipca Labs
2.1
Jubilant Life
Torrent Pharma
1.8
GlaxoSmithKline
1.6
Wockhardt
1.6
1.56
Glenmark
1.54
Divis Labs
1.41
Orchid chemical
1.26
Sanofi India
Nectar Life
1.2
1
Alembic Pharma
0.9
Piramal Enter
0.9
Elder Pharma
0.82
Ajanta Pharma
0.7
Ind-Swift Labs
0.7
0.7
Pfizer
0.7
Unichem Labs
0.66
56.95
14.74
978
13.696
22
11.237
93
9.1308
17
6.3213
35
4.2142
23
3.6874
45
3.5118
53
3.1606
67
2.8094
82
2.8094
82
2.7392
45
2.7041
26
2.4758
56
2.2124
67
2.1071
12
1.7559
26
1.5803
34
1.5803
34
1.4398
6
1.2291
48
1.2291
48
1.2291
48
1.2291
48
1.1589
11
100
217.5
56
187.58
66
126.29
1
83.371
81
39.959
27
17.759
68
13.597
25
12.333
11
9.9898
17
7.8931
89
7.8931
89
7.5034
63
7.3123
6.1298
63
4.8950
11
4.4399
19
3.0832
77
2.4974
54
2.4974
54
2.0731
95
1.5108
06
1.5108
06
1.5108
06
1.5108
06
1.3430
75
772.04
92
Net Sales
Net sales
Sun Pharma
(Rs. cr)
12500.00
in $million
2100.00
Dr Reddys Labs
12,000.00
2000.00
Lupin
Cipla
9461.38
8,202.42
1600.9
1364.3
Aurobindo Pharm
5,425.10
902.4
Cadila Health
3,675.70
614
Ipca Labs
3,234.82
538.1
Jubilant Life
3,146.30
523.3
Torrent Pharma
2,766.23
460.1
GlaxoSmithKline
2,546.15
423.5
Wockhardt
2,471.18
411
2,432.14
404.5
Glenmark
2,300.90
382.7
Divis Labs
2,128.89
354
Orchid Chemical
1,906.58
317.1
Sanofi India
1,808.86
300.9
Nectar Life
1,626.25
270.5
Alembic Pharma
1,492.64
248.3
Piramal Enter
1,403.19
233.4
Elder Pharma
1,233.10
205.1
Ajanta Pharma
1,109.92
184.6
Ind-Swift Labs
1,082.70
180.1
1,059.50
1,050.07
1,005.22
176.2
174.7
167.2
This table shows players in pharmaceutical industry of India by Net Revenue in the Indian market which
have Net Sales above 1000 crore rupees which is equivalent to $160 million.
As of Q1 FY2014 Sun Pharmaceuticals is at the top in Net Revenue at $ 2.1 billion which increased
significantly recently due to the acquisition of Ranbaxy. Dr Reddys Laboratories is second with Net Revenue
amounting to $ 2 billion followed by Lupin with $ 1.6 billion.
Among this list Cipla, Sun Pharmaceuticals and Dr Reddys Laboratories is listed in the SENSEX 30 among
all other pharmaceuticals in India.
Indian pharmaceutical industry is dominated by Indian companies, thus global pharmaceutical giants such as
Pfizer has a Net revenue as $174.7 million and GlaxoSmithkline with $423 million which is quite less
compared to top Indian counterparts in the Indian markets.
Indian Pharmaceutical companies with respect to MARKET CAPITALISATION
Sun Pharma
(Rs. cr)
1,63,559.81
(in million $)
27205.3
Lupin
Dr Reddys Labs
Cipla
49,980.00
47,012.47
35,288.39
8313.3
7819.6
5869.5
Ranbaxy Labs
25,016.79
4161.1
Cadila Health
GlaxoSmithKline
23,118.16
21,041.50
3845.3
3499.9
Aurobindo Pharm
19,789.93
3291.7
Divis Labs
19,604.85
3261
Glenmark
17,851.00
2965.2
Torrent Pharma
12,217.88
2032.1
Piramal Enter
10,978.46
1826.1
Biocon
9,303.00
1547.4
Ipca Labs
8,885.05
1477.9
Wockhardt
7,609.25
1265.7
Sanofi India
6,860.71
1141
Alembic Pharma
6,371.84
1059
Ajanta Pharma
5,816.56
967.5
Abbott India
4,315.84
717.9
4,196.77
698.1
Pfizer
4,115.28
684.5
(Source: www.moneycontrol.com)
The above Table shows key players in the pharmaceutical markets ranked on the basis of market
capitalisation.
Sun pharmaceutical based on market capitalisation is at the top with $ 27 billion followed by Lupin with $8.3
billion and Dr Reddys Pharmaceutical at &$ 7.8 billion while global giants as GlaxoSmithKline with $ 3.4
billion and Pfizer with $ 684 million.
19%
72%
Source: all Indian origin chemists & distributors, dep. of pharmaceuticals, planning commission
report www.ibef.org
72% of market share (in revenue) is generic drug which is highest, currently at $18.3 billion. Over the
counter medicine at 19% (revenue) and patented drug at 9%.
Cardiac
Gastro Intestinal
Vitamins/Minerals/Nutrients
18%
Respiratory
35%
12%
Pain/anaelgesics
Others
11%
7%
8%
9%
Source: all Indian origin chemists & distributors, dep. of pharmaceuticals, planning commission
report www.ibef.org
R&D IN PHARMACEUTICAL
40
20
0
Source: all Indian origin chemists & distributors, dep. of pharmaceuticals, planning commission
report www.ibef.org
Average investment in R&D in pharmaceutical industry in India is 2% of revenue which stands at $ 533
million spending of pharmaceutical in 2013-14.
As the above table shows investment on R&D has significantly been increased by Top Pharma companies in
India. Dr Reddy Labs at $130 million from $82 million which is an increase of $ 48 million. Lupin is ranked
second in investment in Pharmaceutical with $124 million with an increase from $87 million.
The metropolitans and cosmopolitans contribute 30% of the Net sales whereas class 1 towns and class 2-4
towns share 31% and 19% respectively. Rural share 20% of the market with growth of 14%.
Patented
0.8
0.9
1.1
1.3
1.5
1.8
2.2
2.7
3.3
6.9
8.1
10
11.3
12.6
15.1
18.2
21.8
26.1
2008
2009
2010
2011
2012
2013
2014
2015
2016
Currently in prescribed drugs generics commands $18.2 billion whereas patented holds $2.2 billion.
25
23
20
19
15
10
11
13
14
16
5
0
2010
2011
2012
2013
2014
2015
2016
Source: all Indian origin chemists & distributors, dep. of pharmaceuticals, planning commission
report www.ibef.org
Per capita sales in current year are $19 which is expected to grow at $27 by 2016 at a CAGR at 16.3%. This
is primarily dependent at per capita income.
10
(USD) billion
FY06
FY07
FY08
FY09
FY10
FY11
FY12
FY13
Source: all Indian origin chemists & distributors, dep. of pharmaceuticals, planning commission
report www.ibef.org
Ministry of commerce targets to exports 25 billion worth of pharmaceuticals by 2016. Indian drugs are
exported to more than 200 countries in the world. India is the largest producer of generic drug market
accounting for 10% in term of volumes.
In terms of value exports have increased with a CAGR of 26.1%.
Exports are at 10.1 billion and imports are at 1.8 billion. Exports are steeply increasing due to low cost of
manufacturing and labour in India.
Sun
pharm
a
Torrent
pharm
a
Acquir
es
$3.2
billion
ranbax
y
Acquir
es
$
321.6
miilion
elder
Lupin
Acquir
es
Grim
FDI
$10
biilion
MANUFACTURING
India has the largest number of US FDA approved manufacturing plants outside US at 546 out
of 10500.
India has 2633 USFDA approved drug products out of 60000 products.
India accounts for 35.7 per cent (3,000) of 8,374 Drug Master Files (DMFs) filed with the USA,
which is the highest outside of USA.
Cost Of production:
Indias cost of production is nearly 60% lower than that of USA and 50% lower than Europe.
Labour cost is 55% cheaper than USA and Europe.
The cost of setting up a production plant in India is $50% lower than Europe and USA.
Cost efficiency is the one of the crucial reason for increase in export and opportunities for Indian
pharmaceutical industry.
Income
of consumer
i.e a consumers ability to pay is a variable in demand of
Y: Income
of
pharmaceutical
product.
If income of consumer is high he will likely spend more
consumer
on his health and able to spend greater. Thus income of consumer and demand
of pharmaceutical product are in positive relation.
With
increase in literacy and marketing awareness flow of information is
INF:
much
higher. Advertisement, marketing, and education helps to increase
Information
demand of pharmaceutical products . Thus, this has a positive relation to
demand.
Mortality rateis a measure of the number ofdeaths per 1,000
individuals per year. Mortality rates has been steadily declining
in past
decades due to various reasons such as better health care
M:
Mortality
system
Rate and enhanced pharmaceutical product. The lower the
mortality rate greater the number of years will survive and thus
demand better health care and pharmaceuticals in order to stay
healthy. Thus, demand of pharmaceutical and mortality rate have
an inverse relation.
P: Population
Increase
in population has been a vital factor in increase in
demand of Indian pharmaceutical industry and thus there is
excess of demand over supply of pharmaceutical products.
Indian
lifestyle has changed over the years due to
Lf: LifePopulation's
style
socio-economic factors and growing urbanization. This has led
to an increase in life-style related ailments such as obesity,
heart disease, stroke, cancer and diabetes.
Substitute to pharmaceutical products such as ayurvedic, homeopathy
Substitute aspeople opting for it for various medical reasons. However
areS:variable
during serious and critical conditions pharmaceutical products have been
favoured for their effectiveness and efficiency. Ayurvedic industry stands
at $2 billion with company as zandu, patanjali, dabur and homeopathy at
$0.5 billion industry.
OTHER DRUGS
In case of other drug Price is a variable upto a certain extent thus, the
demand curve is not perpendicular.
SWOT ANALYSIS
Cost Efficient
STRENGTH
Talent Base
Low-Cost
Manufacturing
Base
Indias cost of production
is nearly 60% lower than
that of USA and 50% lower
than Europe.
The cost of setting up a
production plant in India is
$50% lower than Europe
and USA which makes India
a high priority destination
for investment in
manufacturing plants.
India has the largest
number of USFDA
manufacturing plant
outside USA.
Robust Generic
Pipeline
India is the largest
producer of generic
medicines in the world in
terms of volume.
R&D
In addition 2 % of revenue
is allocated to R & d for
innovation and reengineering.
WEAKENESS
Price Regulator
In India the national pharma
pricing authority dictates all
the pricing of pharmaceutical
products. They set various
pricing parameters and set
prices which leads to lower
profitability of the pharma
industry which acts as a
barrier for growth and
expansion.
Product Patent
There is lack of prosuct
patent in india which
acts as a hindrance to
innovation and
discouraging
investment from
international companies
Penetration
The pharma industry
has not penetrated
enough in the
population especially
the rural area which
remains 70% untapped
thus, have to rely on
exports for growth and
expansion.
Fragmented
Policies
In india there is
fragmented policies
thus, leading to low
barriers to entry. Which
makes the industry
highly unconcentrated
and competitive which
is deduced by HHI
above.
R u r a l p e n e t r a t io n
P ro d u ct p a te n t
In t h e u .s a n d e u r o p e fr o m
2 0 1 2 -2 0 1 5 m a n y g e n e r ic
m e d ic in e p a t e n t w ill
e x p ir e . T h is le a d s a m p le
o p p o r t u n it y fo r in d ia n
c o m p a n y t o e x p lo it a n d
in t r o d u c e c h e a p e r
a lt e r n a t iv e s e s p e c ia lly in
g e n e r ic d r u g m a r k e t
L Ife s t y le
D e m o g r a p h ic s
In d ia n Po p u la tio n 's life s ty le
h a s c h a n g e d o v e r th e y e a rs
d u e to s o c io -e c o n o m ic fa c to rs
a n d g ro w in g u rb a n iz a tio n . T h is
h a s le d to a n in c re a s e in life s ty le re la te d a ilm e n ts s u c h a s
o b e s ity , h e a r t d is e a s e , s t ro ke ,
c a n c e r a n d d ia b e te s .
R a p id U r b a n is a t io n
It is e s t im a t e d t h a t 4 0 % o f
in d ia n p o p u la t io n w ill liv e
in u r b a n a r e a s u p t o 2 0 3 0
a n d u r b a n p e n e t r a t io n is
in c r e a s in g a t C A G r o f 3 0 % .
T h u s c re a te s o p p o rtu n e
a r e a f o r p h a r m a in d u s t r y.
H e a lt h in s u r a n c e
H e a lt h in s u r a n c e
p e n e t r a t io n is in c r e a s in g in
In d ia b u t o n ly 3 0 % In d ia n
p o p u la t io n is c o v e r e d b y it .
E x p e x te d to re a ch 4 5 % b y
2020.
TCH
R E AT S
o m p e t it io n
C h in a In d ia c o m p e t it iv e
m a r k e t a ls o h a s a r o b u s t
g e n e r ic d r u g p ip e in e
h a v in g m o r e e ff e c ie n t
m a n u fa c t u r in g in d u s t r y.
T h is p o s e s a t h r e a t in
in v e s t m e n t fo r
in t e r n a t io n a l p la y e r s in
In d ia .
Is r a e l is a ls o a lo w c o s t
m a n u f a c t u r e r w h ic h
t h r e a t e n In d ia n
m a n u fa c t u r e r s a n d
e x p o rts.
P a t e n t P o lic y
P a t e n t P o lic y s t r u c t u r e is
q u e s t io n e d b y
In t e r n a t io n a l p la y e r s t h u s ,
G o v e rn m e n t m ay b e
c o m p e lle d t o m o d ify w h ic h
w ill t h r e a t e n t h e d o m e s t ic
m a n u fa c t u r e r s .
E x p o r t R e ly in g
E x c e s s r e ly in g o n
In t e r n a t io n a l m a r k e t m a y
p o s e p r o b le m d u r in g c r is is
a s p e n e t r a t io n in In d ia n
m a r k e t is v e r y lo w .
Source: www.ibef.org
Dr Reddys began as an API manufacturer in 1984.
It has integrated in 3 segments: Pharmaceutical
services & Active ingredients, global generics.
It accesses emerging market with partnership with
GSK.
It revenues increased from $1.5 billion in FY09 to
$2.1 billion in 2014 at Cagr of 14.4 %.
Global generics compromised 71% of its revenues.
Source: www.ibef.org
BIBLIOGRAPHY
www.ibef.org
www.medindia.com
http://www.ncbi.nlm.nih.gov/
www.pharmaceuticals.gov.in/
Economic Times (august edition 2014)